مليىان
bayer israel ltd - ethinylestradiol 0.020 mg; gestodene 0.075 mg - coated tablets - gestodene and estrogen - oral contraceptive.
ىاسمىن
bayer israel ltd - drospirenone 3 mg; ethinylestradiol 0.03 mg - film coated tablets - drospirenone and estrogen - oral contraception.
ىاز
bayer israel ltd - drospirenone 3 mg; ethinylestradiol 0.02 mg - film coated tablets - drospirenone and estrogen - - oral contraception. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms ( premenstrual syndrome ).
تستوڤيرون ديپو
bayer israel ltd - testosterone enantate 250 mg/ml - oily solution for injection - testosterone - testosterone replacement therapy in male hypogonadism, in cases where testosterone deficiency has been confirmed on the basis of clinical and lboratory evidence.inducing puberty in boys with delayed puberty (pubertas tarda).
سىزونىك
salomon,levin & elstein ltd - ethinylestradiol 0.01 mg; ethinylestradiol 0.03 mg - tablets - ethinylestradiol - seasonique is indicated for use by women to prevent pregnancy.
پريمولوت-نور
bayer israel ltd - norethisterone acetate 5 mg - tablets - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.
ديانة ٣٥
bayer israel ltd - cyproterone acetate 2 mg; ethinylestradiol 35 mcg - tablets - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.
أناستروزول تيڤع
teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.